New PET scan tracer could shine a light on hidden pancreatic tumors
NCT ID NCT07340437
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tested a new radioactive tracer called 18F-Exendin-4, used with PET/CT scans, to see if it can better detect insulinoma—a rare tumor in the pancreas that causes dangerously low blood sugar. Twenty participants with confirmed insulinoma received the tracer and underwent imaging. The goal was to compare the scan results with standard tests like MRI and CT. If the new method proves accurate, it could offer a less invasive way to diagnose these tumors.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- 18F-Exendin-4 (a radioactive tracer for PET/CT imaging)
- What this could lead to
- If successful, this imaging method could provide a more accurate, non-invasive way to detect insulinoma, potentially reducing the need for exploratory surgery.
- What could go wrong
- This is a small, early-stage study with only 20 participants, so results may not apply to everyone. The probe's accuracy and safety need further validation in larger trials.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for INSULINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Department of Endocrinology and Department of Nuclear Medicine, Sichuan Provincial People's Hospital, Chengdu, Sichuan 610072
Chengdu, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.